atheroma

Following in the delay in the release of data by Amgen, Inc. (NASDAQ: AMGN) for its ongoing Repatha Phase 3 trials, Goldman Sachs’ Terence Flynn now believes that the Phase 3 IVUS data could be a more important near-term catalyst for the stock. Flynn maintains a Buy rating on the company,...